vs
QUALYS, INC.（QLYS）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
QUALYS, INC.的季度营收约是再鼎医药的1.4倍（$175.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs 10.1%），QUALYS, INC.自由现金流更多（$74.9M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 9.6%）
Qualys是总部位于美国加利福尼亚州福斯特城的科技企业，专注于云安全、合规管理及相关服务，为客户提供覆盖云环境的安全防护与合规解决方案，助力企业应对各类网络安全风险，满足不同行业的合规运营需求。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
QLYS vs ZLAB — 直观对比
营收规模更大
QLYS
是对方的1.4倍
$127.1M
营收增速更快
ZLAB
高出7.0%
10.1%
自由现金流更多
QLYS
多$101.6M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
9.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $175.3M | $127.1M |
| 净利润 | $53.1M | — |
| 毛利率 | 83.4% | 51.0% |
| 营业利润率 | 33.6% | -54.6% |
| 净利率 | 30.3% | — |
| 营收同比 | 10.1% | 17.1% |
| 净利润同比 | 20.9% | — |
| 每股收益（稀释后） | $1.47 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QLYSZLAB
| Q4 25 | $175.3M | $127.1M | ||
| Q3 25 | $169.9M | $115.4M | ||
| Q2 25 | $164.1M | $109.1M | ||
| Q1 25 | $159.9M | $105.7M | ||
| Q4 24 | $159.2M | $108.5M | ||
| Q3 24 | $153.9M | $101.8M | ||
| Q2 24 | $148.7M | $100.1M | ||
| Q1 24 | $145.8M | $87.1M |
净利润QLYSZLAB
| Q4 25 | $53.1M | — | ||
| Q3 25 | $50.3M | $-36.0M | ||
| Q2 25 | $47.3M | $-40.7M | ||
| Q1 25 | $47.5M | $-48.4M | ||
| Q4 24 | $44.0M | — | ||
| Q3 24 | $46.2M | $-41.7M | ||
| Q2 24 | $43.8M | $-80.3M | ||
| Q1 24 | $39.7M | $-53.5M |
毛利率QLYSZLAB
| Q4 25 | 83.4% | 51.0% | ||
| Q3 25 | 83.6% | 59.5% | ||
| Q2 25 | 82.4% | 60.6% | ||
| Q1 25 | 81.9% | 63.6% | ||
| Q4 24 | 81.8% | 61.5% | ||
| Q3 24 | 81.3% | 64.1% | ||
| Q2 24 | 82.2% | 64.9% | ||
| Q1 24 | 81.3% | 61.4% |
营业利润率QLYSZLAB
| Q4 25 | 33.6% | -54.6% | ||
| Q3 25 | 35.3% | -42.3% | ||
| Q2 25 | 31.3% | -50.3% | ||
| Q1 25 | 32.4% | -53.3% | ||
| Q4 24 | 31.0% | -62.6% | ||
| Q3 24 | 29.2% | -66.6% | ||
| Q2 24 | 32.3% | -76.0% | ||
| Q1 24 | 30.7% | -80.7% |
净利率QLYSZLAB
| Q4 25 | 30.3% | — | ||
| Q3 25 | 29.6% | -31.2% | ||
| Q2 25 | 28.8% | -37.3% | ||
| Q1 25 | 29.7% | -45.8% | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 30.0% | -40.9% | ||
| Q2 24 | 29.4% | -80.2% | ||
| Q1 24 | 27.2% | -61.4% |
每股收益（稀释后）QLYSZLAB
| Q4 25 | $1.47 | $-0.05 | ||
| Q3 25 | $1.39 | $-0.03 | ||
| Q2 25 | $1.29 | $-0.04 | ||
| Q1 25 | $1.29 | $-0.04 | ||
| Q4 24 | $1.19 | $-0.09 | ||
| Q3 24 | $1.24 | $-0.04 | ||
| Q2 24 | $1.17 | $-0.08 | ||
| Q1 24 | $1.05 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $250.3M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $561.2M | $715.5M |
| 总资产 | $1.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资QLYSZLAB
| Q4 25 | $250.3M | $689.6M | ||
| Q3 25 | $225.3M | $717.2M | ||
| Q2 25 | $194.0M | $732.2M | ||
| Q1 25 | $290.7M | $757.3M | ||
| Q4 24 | $232.2M | $779.7M | ||
| Q3 24 | $235.4M | $616.1M | ||
| Q2 24 | $281.2M | $630.0M | ||
| Q1 24 | $273.8M | $650.8M |
股东权益QLYSZLAB
| Q4 25 | $561.2M | $715.5M | ||
| Q3 25 | $529.4M | $759.9M | ||
| Q2 25 | $508.2M | $791.7M | ||
| Q1 25 | $498.0M | $810.8M | ||
| Q4 24 | $477.1M | $840.9M | ||
| Q3 24 | $449.6M | $667.7M | ||
| Q2 24 | $427.8M | $704.2M | ||
| Q1 24 | $404.2M | $762.2M |
总资产QLYSZLAB
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.0B | $1.2B | ||
| Q2 25 | $999.5M | $1.2B | ||
| Q1 25 | $996.5M | $1.2B | ||
| Q4 24 | $973.5M | $1.2B | ||
| Q3 24 | $908.3M | $985.3M | ||
| Q2 24 | $876.6M | $987.4M | ||
| Q1 24 | $861.8M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.7M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $74.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | 42.8% | -21.0% |
| 资本支出强度资本支出/营收 | 0.4% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.42× | — |
| 过去12个月自由现金流最近4个季度 | $304.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流QLYSZLAB
| Q4 25 | $75.7M | $-26.0M | ||
| Q3 25 | $90.4M | $-32.0M | ||
| Q2 25 | $33.8M | $-31.0M | ||
| Q1 25 | $109.6M | $-61.7M | ||
| Q4 24 | $47.7M | $-55.8M | ||
| Q3 24 | $61.0M | $-26.8M | ||
| Q2 24 | $49.8M | $-42.2M | ||
| Q1 24 | $85.5M | $-90.1M |
自由现金流QLYSZLAB
| Q4 25 | $74.9M | $-26.7M | ||
| Q3 25 | $89.5M | $-35.0M | ||
| Q2 25 | $32.4M | $-33.9M | ||
| Q1 25 | $107.5M | $-63.2M | ||
| Q4 24 | $41.9M | $-58.4M | ||
| Q3 24 | $57.6M | $-28.2M | ||
| Q2 24 | $48.8M | $-42.9M | ||
| Q1 24 | $83.5M | $-91.1M |
自由现金流率QLYSZLAB
| Q4 25 | 42.8% | -21.0% | ||
| Q3 25 | 52.7% | -30.4% | ||
| Q2 25 | 19.8% | -31.1% | ||
| Q1 25 | 67.3% | -59.9% | ||
| Q4 24 | 26.3% | -53.8% | ||
| Q3 24 | 37.4% | -27.7% | ||
| Q2 24 | 32.8% | -42.9% | ||
| Q1 24 | 57.2% | -104.5% |
资本支出强度QLYSZLAB
| Q4 25 | 0.4% | 0.5% | ||
| Q3 25 | 0.5% | 2.6% | ||
| Q2 25 | 0.8% | 2.6% | ||
| Q1 25 | 1.3% | 1.5% | ||
| Q4 24 | 3.7% | 2.4% | ||
| Q3 24 | 2.2% | 1.3% | ||
| Q2 24 | 0.7% | 0.7% | ||
| Q1 24 | 1.4% | 1.1% |
现金转化率QLYSZLAB
| Q4 25 | 1.42× | — | ||
| Q3 25 | 1.80× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 2.31× | — | ||
| Q4 24 | 1.09× | — | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.14× | — | ||
| Q1 24 | 2.15× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QLYS
| Sales Channel Through Intermediary | $88.6M | 51% |
| Sales Channel Directly To Consumer | $86.7M | 49% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
